Repligen Corp (RGEN) · Nov 6, 2026 · New debt

Repligen debt refinancing closes, adding cash but leverage rises

Debt refinanced — 0.25% coupon; $458.6M cash issuance; $143.2M of 2028 notes remain

Repligen’s debt refinancing is complete: a lower coupon and longer maturity improve flexibility, but the company adds substantial new debt after BioLife.

Repligen is a bioprocessing-equipment and consumables company in an expansion phase, using the recently completed BioLife acquisition to broaden its cell-therapy offering while demand and full-year growth guidance are improving.

The financing is now complete, not newly discovered. Repligen issued $1.0 billion of 0.25% convertible notes due 2031, with roughly $541.4 million exchanged for its 2028 notes and $458.6 million sold for cash. Because the transaction terms were announced before closing, the event is confirmation rather than a fresh strategic surprise.

The structure improves near-term financing flexibility. Most of the 2028 maturity has been pushed out to 2031, while the coupon falls from 1.00% to 0.25%. Only $143.2 million of the old notes remains outstanding. That reduces refinancing pressure and lowers stated cash interest, useful after the BioLife acquisition.

The trade-off is a materially larger debt balance. The cash subscription adds $458.6 million of new borrowings, so this is not merely a maturity swap; it gives Repligen more liquidity but also increases financial obligations as it integrates BioLife. The new notes initially convert at approximately $226.37 per share, a 20% premium to the October 29 closing price, which limits immediate dilution but leaves future equity dilution as a possibility.

LabelNew Notes2028 NotesCash / reference
Principal (New Notes) (New Notes)$1.0B$456.8M exchanged$458.6M issued for cash
Coupon (New Notes)0.25%1.00%
Maturity (New Notes)20312028
Conversion price (New Notes)$226.3720% premium
2028 notes remaining (New Notes)$143.2M

Bottom line: This is a completed, previously telegraphed refinancing that gives Repligen cheaper and longer-dated debt plus fresh liquidity, but at the cost of higher leverage. It supports the BioLife-led expansion story without materially changing it today.

Original filing on SEC EDGAR

More Repligen Corp news

Repligen debt refinancing closes, adding cash but leverage rises | RGEN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.